Skip to main content

Table 3 Compliance with Home Blood Pressure Monitoring and Blood Pressure Control

From: Effect of home blood pressure monitoring for blood pressure control in hypertensive patients taking multiple antihypertensive medications including fimasartan (the FORTE study)

 

Odds Ratio

 

Point Estimate

95% CI

P-value

Age

1.009

(0.997, 1.021)

0.1237

Sex

0.816

(0.616, 1.080)

0.1546

Target organ damagea

0.792

(0.568, 1.104)

0.1691

Home sphygmomanometers at baseline

0.900

(0.665, 1.217)

0.4923

Baseline SBP

0.998

(0.988, 1.008)

0.6615

Baseline DBP

0.986

(0.972, 1.000)

0.0519

Dyslipidemiab

0.804

(0.571, 1.131)

0.2105

FBS ≥100 mg/dL

0.601

(0.421, 0.857)

0.0050

Central obesity (men ≥90 cm, women ≥80 cm)

1.460

(1.070, 1.992)

0.0171

Family history of cardiovascular disease (men < 55 years, women < 65 years)

1.429

(0.584, 3.495)

0.4342

Compliance with HBP (0% vs. over 0%)

1.602

(1.182, 2.172)

0.0024

  1. SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood glucose, BMI body mass index, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
  2. aTarget organ damage was defined as a composite of 1) stroke, transient ischemic attack, or vascular dementia; 2) left ventricular hypertrophy, angina, myocardiac infarction, or heart failure; 3) albuminuria (albumin level > 30 mg/g) or chronic kidney disease (eGFR < 60 mL/min/1.73 m2); 4) peripheral vascular disease (ankle-brachial index < 0.9), pulse wave velocity > 10 m/sec, intimal thickness of the carotid artery > 1.0 mm or large artery disease; and 5) stage 3 or 4 hypertensive retinopathy
  3. bDyslipidemia was defined as total cholesterol level ≥ 230 mg/dL, LDL-C level ≥ 150 mg/dL, HDL-C level < 40 mg/dL, or triglyceride ≥200 mg/dL